Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301497 | 0.98 | DGAT1 (0.46) | DGAT1SCN10ASCN2AGPBAR1PROKR1 | |
| SCHEMBL31301409 | 0.97 | DGAT1 (0.45) | DGAT1SCN10ASCN2AGPBAR1PROKR1 | |
| SCHEMBL34461742 | 0.97 | DGAT1 (0.45) | DGAT1SCN10ASCN2AGPBAR1PROKR1 | |
| SCHEMBL31301435 | 0.88 | SCN10A (0.53) | SCN10ASCN2AGPBAR1PIK3CDPIK3CB | |
| SCHEMBL31301480 | 0.83 | SCN10A (0.55) | SCN10ASCN2AGPBAR1PIK3CDPIK3CB | |
| SCHEMBL31301346 | 0.83 | SCN10A (0.55) | SCN10ASCN2AGPBAR1PIK3CDPIK3CB | |
| SCHEMBL31301446 | 0.82 | DGAT1 (0.49) | DGAT1GPBAR1 | |
| SCHEMBL31301588 | 0.81 | SCN10A (0.47) | SCN10ASCN2AGPBAR1PIK3CDPIK3CB | |
| SCHEMBL31301415 | 0.80 | SCN10A (0.52) | SCN10ASCN2AGPBAR1PIK3CDPIK3CB | |
| SCHEMBL31301324 | 0.79 | SCN10A (0.46) | SCN10ASCN2AGPBAR1PIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | DGAT1 1115/4885SCN10A 3171/4885SCN2A 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.